Combining talimogene laherparepvec (T-VEC) with pembrolizumab did not lead to a survival benefit for patients with advanced melanoma.
2021
Relatlimab / Nivolumab Improves TFI and PFS2 in Frontline Advanced Melanoma
The addition of relatlimab to nivolumab (Opdivo) prolonged benefit beyond initial treatment and first progression and reduced the risk of progression…
Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma
Adjuvant pembrolizumab (Keytruda) led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma…
Meet The Mexican Cancer Scientist Unlocking Melanoma Mysteries
In many countries, melanoma skin cancers are caused by UV radiation, but that’s not the case for a mysterious melanoma being studied by Mexican scientist Dr Carla Daniela Robles-Espinoza.